(Total Views: 366)
Posted On: 06/08/2017 2:07:39 PM
Post# of 11803
Re: weaver_525 #741
For what its worth, if I were to forecast the GenPrecis product from DECN, and there will be multiple bidders for the product if DECN decides to partner with one of the giants, but I would forecast 6% market share in the U.S. after 3 full years post FDA pre-market.
The diabetes arena has seen enough of the cheap Chinese products, and enough of the feature rich, over-priced meter entries from the Big 4, but the diabetes world has not seen (yet) an affordable feature rich meter along with a test strip that is a +/- 10% 97% of the time. That would make GenPrecis 33% better than everyone else.
Just my opinion. But GenPrecis could be a $15-$25 million cash sale product if it is licensed to a legit partner (hopefully my company who desperately needs a new and better product). Even more if GenPrecis is sold by its creators.
However, like I have said, technical innovation doesn't matter. Profits don't really matter. Having a once in a generation product doesn't matter. The only thing that matters is share price and message board posters have made that soooo clear.
The diabetes arena has seen enough of the cheap Chinese products, and enough of the feature rich, over-priced meter entries from the Big 4, but the diabetes world has not seen (yet) an affordable feature rich meter along with a test strip that is a +/- 10% 97% of the time. That would make GenPrecis 33% better than everyone else.
Just my opinion. But GenPrecis could be a $15-$25 million cash sale product if it is licensed to a legit partner (hopefully my company who desperately needs a new and better product). Even more if GenPrecis is sold by its creators.
However, like I have said, technical innovation doesn't matter. Profits don't really matter. Having a once in a generation product doesn't matter. The only thing that matters is share price and message board posters have made that soooo clear.
(4)
(1)
